HE4 in ovarian cancer: From Discovery to clinical application.

Advances in Clinical Chemistry

Volumn 55, Issue , 2011, Pages 1-20

  Montagnana, M ^a   Danese, E ^a   Giudici, S ^a   Franchi, M ^b   Guidi, G C ^a   Plebani, M ^b   Lippi, G ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b Univ Hospital of Padova   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Biomarker cancer; HE4; Human epididymis protein 4; Ovarian cancer

Indexed keywords

EID: 80052663966     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387042-1.00001-0     Document Type: Chapter

References (139)

1. Clarke-Pearson D.L. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 2009, 361:170-177.
2. Schorge J.O., Modesitt S.C., Coleman R.L., et al. SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecol. Oncol. 2010, 119:7-17.
3. US Cancer Statistics Working Group United States Cancer Statistics: 1999-2006 Incidence and Mortality Web-based Report 2010, Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta (GA), Available at:, (accessed October 2010). http://www.cdc.gov/uscs.
4. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N. Engl. J. Med. 1990, 322:1021-1027.
5. Partridge E.E., Barnes M.N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J. Clin. 1999, 49:297-320.
6. Sturgeon C.M., Duffy M.J., Stenman U.H., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 2008, 54:e11-e79.
7. Ballesta A.M., Molina R. Tumor markers: definition and classification. Up Dating on Tumor Markers in Tissues and in Biological Fluids Basic Aspects and Clinical Applications 1993, 75-88. Edizioni Minerva Medica, Torino. A.M. Ballesta, G.C. Torre, E. Bombardieri, M. Gion, R. Molina (Eds.).
8. Willmott L.J., Fruehauf J.P. Targeted therapy in ovarian cancer. J. Oncol. 2010, 2010:740472.
9. Bonfrer J.M.G., Duffy M.J., Radtke M., et al. Tumour markers in gynaecological cancers: EGTM recommendations. Anticancer Res. 1999, 19:2807-2810.
10. Duffy M.J., Bonfrer J.M., Kulpa J., et al. CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int. J. Gynecol. Cancer 2005, 15:679-691.
11. NIH consensus conference Ovarian cancer: screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995, 273:491-497.
12. Meyer T., Rustin G.J. Role of tumour markers in monitoring epithelial ovarian cancer. Br. J. Cancer 2000, 182:1535-1538.
13. Diamandis E.P. Cancer biomarkers: can we turn recent failures into success?. J. Natl. Cancer Inst. 2010, 102:1462-1467.
14. Bast R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 1983, 309:883-887.
15. Moss E.L., Hollingworth J., Reynolds T.M. The role of CA125 in clinical practice. J. Clin. Pathol. 2005, 58:308-312.
16. Köbel M., Kalloger S.E., Boyd N., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008, 5:e232.
17. Sturgeon C., McAllister E.J. Analysis of HCG. Clinical applications and assay requirements. Ann. Clin. Biochem. 1998, 35:460.
18. Begent R.H.J. The value of carcinoembryonic antigen measurement in clinical practice. Ann. Clin. Biochem. 1984, 21:231.
19. Bast R.C., Badgwell D., Lu Z., et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 2005, 15(Suppl. 3):274-281.
20. Høgdall E.V., Christensen L., Kjaer S.K., et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish " MALOVA" Ovarian Cancer Study. Gynecol. Oncol. 2007, 104:508-515.
21. Daoud E., Bodor G. CA-125 concentrations in malignant and nonmalignant disease. Clin. Chem. 1991, 37:1968-1974.
22. Visser C.E., Brouwer-Steenbergen J.J., Betjes M.G., Koomen G.C., Beelen R.H., Krediet R.T. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol. Dial. Transplant. 1995, 10:64-69.
23. Hwang J., Na S., Lee H., Lee D. Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial ovarian cancer. J. Gynecol. Oncol. 2009, 20:169-175.
24. But I., Gorisek B. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer. Gynecol. Oncol. 1996, 63:166-172.
25. Rossi A.C., Di Vagno G., Cormio G., et al. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer. Arch. Gynecol. Obstet. 2004, 269:263-265.
26. Tuxen M.K., Soletormos G., Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev. 1995, 21:215-245.
27. Mobus V., Kreienberg R., Crombach G. Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer. J. Tumor Marker Oncol. 1988, 3:251-258.
28. Geisler J.P., Miller G.A., Lee T.H., Harwood R.M., Wiemann M.C., Geisler H.E. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J. Reprod. Med. 1996, 41:140-142.
29. Kudoh K., Kikuchi Y., Kita T., et al. Preoperative determination of several tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol. Obstet. Invest. 1999, 47:52-57.
30. Gadducci A., Zola P., Landoni F., et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol. Oncol. 1995, 58:42-47.
31. Makar A.P., Kristensen G.B., Kaern J., Bormer O.P., Abeler V.M., Trope C.G. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet. Gynecol. 1992, 79:1002-1010.
32. Makar A.P., Kristensen G.B., Børmer O.P., Tropé C.G. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?. Gynecol. Oncol. 1993, 49:3-7.
33. Colakovic S., Lukic V., Mitrovic L., Jelic S., Susnjar S., Marinkovic J. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int. J. Biol. Markers 2000, 15:147-152.
34. Brand E., Lidor Y. The decline of CA 125 level after surgery reflects the size of residual ovarian cancer. Obstet. Gynecol. 1993, 81:29-32.
35. Rosen A., Sevelda P., Klein M., Spona J., Beck A. A CA 125 score as a prognostic index in patients with ovarian cancer. Arch. Gynecol. Obstet. 1990, 247:125-129.
36. Gundogdu F., Soylu F., Erkan L., Tatli O., Mavi S., Yavuzcan A. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Arch. Gynecol. Obstet. 2011, 283:1397-1402.
37. Gupta D., Lis C.G. Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. J. Ovarian Res. 2009, 2:13.
38. Cooper B.C., Sood A.K., Davis C.S., et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet. Gynecol. 2002, 100:59-64.
39. Rose P.G., Terrien J.M., Baker S. Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. J. Surg. Oncol. 1994, 56:168-171.
40. Selman A.E., Copeland L.J. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma. Curr. Oncol. Rep. 1999, 1:71-76.
41. Wong C., Dai Z.M., Lele S.B., Natarajan N. Comparison of CA 125 after three courses of chemotherapy and results of second-look surgery. Eur. J. Gynaecol. Oncol. 2000, 21:70-73.
42. Gadducci A., Landoni F., Maggino T., et al. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int. J. Gynecol. Cancer 1997, 7:78-83.
43. Buller R.E., Disaia P.J. An ovarian cancer tumor marker, CA 125, comes of age. West. J. Med. 1990, 152:406-407.
44. Johnson C.C., Kessel B., Riley T.L., et al. Prostate, Lung, Colorectal and Ovarian Cancer Project Team. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol. Oncol. 2008, 110:383-389.
45. Sevinc A., Adli M., Kalender M.E., Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007, 8:1054-1055.
46. Sevinc A., Buyukberber S., Sari R., Turk H.M., Ates M. Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res. 2000, 20:1201-1204.
47. Sevinc A., Buyukberber S., Sari R., Kiroglu Y., Turk H.M., Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol. Oncol. 2000, 77:254-257.
48. Sari R., Yildirim B., Sevinc A., Hilmioglu F. Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am. J. Gastroenterol. 2001, 96:253-254.
49. Sevinc A., Buyukberber S., Sari R. Elevated serum CA-125 levels: hepatitis or ascites?. Gynecol. Oncol. 2000, 76:141-142.
50. Takahashi N., Shimada T., Ishibashi Y., Oyake N., Murakami Y. Transient elevation of serum tumor markers in a patient with hypothyroidism. Am. J. Med. Sci. 2007, 333:387-389.
51. Sevinc A., Camci C., Turk H.M., Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003, 65:1-6.
52. Ahmed A.S., Long M., Donaldson D. Lessons to be learned: a case study approach: ascites and elevated serum CA 125 due to a pancreatic carcinoma. A diagnostic dilemma. J. R. Soc. Health 2000, 120:47-51.
53. Sevinc A., Sari R., Camci C., Buyukberber S. A secondary interpretation is needed on serum CA 125 levels in case of serosal involvement. J. R. Soc. Health 2000, 120:268-270.
54. Kanehara H., Bando Y., Tomita M., Kontani M., Takegoshi Y., Tanaka N. Myxedema ascites with an extremely elevated CA125 Level: a case report. Endocr. J. 2007, 54:601-604.
55. Takeda N., Ihn H., Teramoto S. Markedly increased levels of IL-6 and CA125 in pleural fluids of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing 2001, 30:171.
56. Szekanecz E., Sándor Z., Antal-Szalmás P., et al. Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation?. Ann. N. Y. Acad. Sci. 2007, 1108:359-371.
57. Lehtovirta P., Apter D., Stenman U.H. Serum CA 125 levels during the menstrual cycle. Br. J. Obstet. Gynaecol. 1990, 97:930-933.
58. Kobayashi F., Sagawa N., Nakamura K., et al. Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am. J. Obstet. Gynecol. 1989, 160:563-566.
59. Check J.H., Nowroozi K., Winkel C.A., Johnson T., Seefried L. Serum CA 125 levels in early pregnancy and subsequent spontaneous abortion. Obstet. Gynecol. 1990, 75:742-744.
60. Cecchi E., Lapi F., Vannacci A., Banchelli G., Mazzei T., Mugelli A. Increased levels of CA 125 and CA 19.9 serum tumour markers following cyclic combined hormone replacement therapy. J. Clin. Pharm. Ther. 2009, 34:129-132.
61. Pauler D.K., Menon U., McIntosh M., Symecko H.L., Skates S.J., Jacobs I.J. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2001, 10:489-493.
62. Latterich M., Abramovitz M., Leyland-Jones B. Proteomics: new technologies and clinical applications. Eur. J. Cancer 2008, 44:2737-2741.
63. Sharon D., Chen R., Snyder M. Systems biology approaches to disease marker discovery. Dis. Markers 2010, 28:209-224.
64. Meyer L.A., Anderson M.E., Lacour R.A., et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet. Gynecol. 2010, 115:945-952.
65. Merritt M.A., Parsons P.G., Newton T.R., et al. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer 2009, 9:378.
66. Chien J., Fan J.B., Bell D.A., et al. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol. Oncol. 2009, 114:3-11.
67. Lu K.H., Patterson A.P., Wang L., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10:3291-3300.
68. Schwartz D.R., Wu R., Kardia S.L., et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res. 2003, 63:2913-2922.
69. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 2001, 98:1176-1181.
70. Kallioniemi A. CGH microarrays and cancer. Curr. Opin. Biotechnol. 2008, 19:36-40.
71. Birrer M.J., Johnson M.E., Hao K., et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin. Oncol. 2007, 25:2281-2287.
72. Sham J.S., Tang T.C., Fang Y., et al. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet. Cytogenet. 2002, 133:39-44.
73. Osterberg L., Levan K., Partheen K., et al. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer 2009, 9:368.
74. Dimova I., Orsetti B., Negre V., et al. Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 2009, 95:357-366.
75. Tejpar S., Bertagnolli M., Bosman F., et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010, 15:390-404.
76. Song H., Ramus S.J., Tyrer J., et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 2009, 41:996-1000.
77. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10:687-692.
78. McHugh S.M., O'Donnell J., Gillen P. Genomic and oncoproteomic advances in detection and treatment of colorectal cancer. World J. Surg. Oncol. 2009, 7:36.
79. Shen L., Waterland R.A. Methods of DNA methylation analysis. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:576-581.
80. Zilberman D., Henikoff S. Genome-wide analysis of DNA methylation patterns. Development 2007, 134:3959-3965.
81. Ho C.M., Lai H.C., Huang S.H., Chien T.Y., Lin M.C., Chang S.F. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur. J. Clin. Invest. 2010, 40:310-318.
82. Teschendorff A.E., Menon U., Gentry-Maharaj A., et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 2009, 4:e8274.
83. Blackstock W.P., Weir M.P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 1999, 17:121-127.
84. Wulfkuhle J.D., Paweletz C.P., Steeg P.S., Petricoin E.F., Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol. 2003, 532:59-68.
85. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5:845-856.
86. Chatterjee S.K., Zetter B.R. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005, 1:37-50.
87. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 2004, 3:367-378.
88. Hanash S. Disease proteomics. Nature 2003, 422:226-232.
89. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
90. Ransohoff D.F. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 2007, 60:1205-1219.
91. Kozak K.R., Su F., Whitelegge J.P., Faull K., Reddy S., Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4589-4596.
92. Su F., Lang J., Kumar A., et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomarker Insights 2007, 2:369-375.
93. El Ayed M., Bonnel D., Longuespée R., et al. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med. Sci. Monit. 2010, 16:BR233-BR245.
94. Meinhold-Heerlein I., Bauerschlag D., Zhou Y., et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin. Cancer Res. 2007, 13:458-466.
95. Wang P., Whiteaker J.R., Paulovich A.G. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol. Ther. 2009, 8:1083-1094.
96. Sturgeon C.M., Hoffman B.R., Chan D.W., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin. Chem. 2008, 54:e1-e10.
97. Kilpatrick E.S., Lind M.J. Appropriate requesting of serum tumour markers. BMJ 2009, 339:b3111.
98. McGinley P.J., Kilpatrick E.S. Tumour markers: their use and misuse by clinicians. Ann. Clin. Biochem. 2003, 40:643-647.
99. Plebani M. The detection and prevention of errors in laboratory medicine. Ann. Clin. Biochem. 2010, 47:101-110.
100. Sonntag O. Analytical interferences and analytical quality. Clin. Chim. Acta 2009, 404:37-40.
101. Mongia S.K., Rawlins M.L., Owen W.E., Roberts W.L. Performance characteristics of seven automated CA 125 assays. Am. J. Clin. Pathol. 2006, 125:921-927.
102. van Dalen A. Analytical requirements and standardization of CA 15-3. Scand. J. Clin. Lab. Invest. Suppl. 1995, 221:102-104.
103. Fraser C.G. Inherent biological variation and reference values. Clin. Chem. Lab. Med. 2004, 42:758-764.
104. Plebani M., Giacomini A., Beghi L., et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res. 1996, 16:2249-2252.
105. Trapé J., Pérez de Olaguer J., Buxó J., Lopez L. Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer. Clin. Chem. 2005, 51:219-222.
106. Ricós C., Alvarez V., Cava F., et al. Desirable specifications for total error, and bias, derived from biologic variation (accessed October 2010). http://www.westgard.com/biodatabase1.htm.
107. Tuxen M.K., Sölétormos G., Petersen P.H., Dombernowsky P. Interpretation of sequential measurements of cancer antigen 125 (CA 125) carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer. Clin. Chem. Lab. Med. 2001, 39:531-538.
108. Tuxen M., Sölétormos G., Petersen P.H., Schioler V., Dombernowsky P. Assessment of biological variation and analytical imprecision of CA 125, CEA and TPA in relation to monitoring of ovarian cancer. Gynecol. Oncol. 1999, 74:12-22.
109. Kirchhoff C., Habben I., Ivell R., Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 1991, 45:350-357.
110. Clauss A., Lilja H., Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem. J. 2002, 368:233-242.
111. Schalkwijk J., Wiedow O., Hirose S. The trappin gene family: proteins defined by an N terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J. 1999, 340:569-577.
112. Hiemstra P.S. Novel roles of protease inhibitors in infection and inflammation. Biochem. Soc. Trans. 2002, 30:116-120.
113. Simpson A.J., Maxwell A.I., Govan J.R., Haslett C., Sallenave J.M. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett. 1999, 452:309-313.
114. McMichael J.W., Roghanian A., Jiang L., Ramage R., Sallenave J.M. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am. J. Respir. Cell Mol. Biol. 2005, 32:443-452.
115. Jin F.Y., Nathan C., Radzioch D., Ding A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997, 88:417-426.
116. Vachon E., Bourbonnais Y., Bingle C.D., Rowe S.J., Janelle M.F., Tremblay G.M. Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol. Chem. 2002, 383:1249-1256.
117. Kirchhoff C. Molecular characterization of epididymal proteins. Rev. Reprod. 1998, 3:86-95.
118. Bingle L., Singleton V., Bingle C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21:2768-2773.
119. Schummer M., Ng W.V., Bumgarner R.E., et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238:375-385.
120. Wang K., Gan L., Jeffery E., et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999, 229:101-108.
121. Hough C.D., Sherman-Baust C.A., Pizer E.S., et al. Large scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60:6281-6287.
122. Gilks C.B., Vanderhyden B.C., Zhu S., van de Rijn M., Longacre T.A. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol. Oncol. 2005, 96:684-694.
123. Schaner M.E., Ross D.T., Ciaravino G., et al. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 2003, 14:4376-4386.
124. Schwartz D.R., Kardia S.L., Shedden K.A., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002, 62:4722-4729.
125. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65:2162-2169.
126. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 2006, 19:847-853.
127. Hellström I., Raycraft J., Hayden-Ledbetter M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63:3695-3700.
128. Havrilesky L.J., Whitehead C.M., Rubatt J.M., et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 2008, 110:374-382.
129. Moore R.G., McMeekin D.S., Brown A.K., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112:40-46.
130. Moore R.G., Brown A.K., Miller M.C., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008, 108:402-408.
131. Shah C.A., Lowe K.A., Paley P., et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1365-1372.
132. Huhtinen K., Suvitie P., Hiissa J., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 2009, 100:1315-1319.
133. Montagnana M., Lippi G., Danese E., Franchi M., Guidi G.C. Usefulness of serum HE4 in endometriotic cysts. Br. J. Cancer 2009, 101:548.
134. Bordin L., Fiore C., Donà G., et al. Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil. Steril. 2010, 94:1616-1621.
135. Moore R.G., Brown A.K., Miller M.C., et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008, 110:196-201.
136. Montagnana M., Lippi G., Danese E., Ruzzenente O., Franchi M., Guidi G.C. Human Epydidimis Protein 4 (HE4): it could be useful in vulvar cancer?. Clin. Lab. 2010, 56:601-602.
137. Nolen B., Velikokhatnaya L., Marrangoni A., et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol. Oncol. 2010, 117:440-445.
138. Montagnana M., Danese E., Ruzzenente O., et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin. Chem. Lab. Med. 2011, 49:521-525.
139. Plebani M. Il trasferimento delle conoscenze sui nuovi biomarcatori: dalla ricerca all'i-phone. Clin. Biochem. 2010, 34:583-584.